Key Facts

IndustryPharmaceutical Contract Developer and Contract Manufacturer (CDMO)
Business ModelDevelopment and production of pharmaceutical products on behalf of customers , as well as the development, production and sales of own products.
Turnoverca. 20 million euros p/a
Staff complement140
Acquisition dateOctober 2013
Investor advised by DUBAGLenbach Equity Opportunities I. SCSp
ExitThe company was divested to Daicel corporation in August 2018

Operational Details

Initial and/or special situation
  • Non-core subsidiary former shareholder, a medium-sized business group
  • High debt level of debt, commitment of the banks was failing
  • Declining, low turnover due to the absence of a sales force
  • General lack of structures / functions in the company
  • High single-customer concentration
Turnaround results
  1. Successful implementation of a sales department
  2. Missing structures were created and new positions were filled
  3. Expansion of the existing customer base
  4. Significant reduction of financial liabilities
  5. Reintroduction of „own“ products
  6. Significant increase in sales and earnings

Further Case Studies